Baseline characteristics
| Total (n=72) | PE (n=34) | No PE (n=38) | |
| Age (years) | |||
| Median (range) | 67 (35, 89) | 62 (35, 85) | 74.5 (35, 89) |
| Sex (N, %) | |||
| Female | 35 (48.61%) | 14 (41.18%) | 21 (55.26%) |
| Male | 37 (51.39%) | 20 (58.82%) | 17 (44.74%) |
| Primary cancer site (n, %) | |||
| Gastrointestinal | 23 (31.94%) | 13 (38.82%) | 10 (26.32%) |
| Gynaecological | 9 (12.50%) | 5 (14.71%) | 4 (10.53%) |
| Breast | 7 (9.72%) | 4 (11.76%) | 3 (7.89%) |
| ENT | 8 (11.11%) | 4 (11.76%) | 4 (10.53%) |
| Lung | 6 (8.33%) | 3 (8.82%) | 3 (7.89%) |
| haemato-oncological | 4 (5.56%) | 1 (2.94%) | 3 (7.89%) |
| Prostate | 4 (5.56%) | 2 (5.88%) | 2 (5.26%) |
| Renal cell | 3 (4.17%) | 0 | 3 (7.89%) |
| Urothelial | 3 (4.17%) | 1 (2.94%) | 2 (5.26%) |
| CUP | 2 (2.78%) | 1 (2.94%) | 1 (2.63%) |
| Other | 3 (4.17) | 0 | 3 (7.89%) |
| Peritoneal/gastrointestinal metastases | 15 (20.83%) | 12 (35.29%) | 3 (7.89%) |
| Survival at 4 weeks follow-up | 38 (52.78%) | 17 (50.00%) | 21 (55.26%) |
CUP, Cancer of Unknown Primary; ENT, Ear, Nose and Throat; PE, Parenteral Nutrition.